WASHINGTON Generic Pharmaceutical Association president and CEO Kathleen Jaeger will leave the organization effective June 30, the industry group said Tuesday.
“I think it was just a recognition from her perspective that it was time for a change,” GPhA chairman and president and CEO of Watson Pharmaceuticals Paul Bisaro told Drug Store News. Bisaro said the organization would soon begin looking for a replacement. “Kathleen has taken us a very long way, and hopefully we can find someone who can take us further.”
Jaeger began working for the organization in 2002, shortly after its formation. Since then, she has become one of the leading voices of the generic drug industry and a strong advocate on issues facing the industry, such as biosimilars.
“It has been a distinct honor to represent GPhA these past eight years and help build a strong, vibrant trade association,” Jaeger said in a statement. “I am extremely proud of the work that the GPhA team has accomplished. Our industry has achieved many victories that have greatly contributed to improving the lives of countless Americans. And today, despite David and Goliath comparisons, the GPhA team has tremendously enhanced the visibility and influence of the trade association, and we’ve been successful at getting a seat at the table in critical industry debates.”
Jaeger’s resignation comes shortly after news that Israel-based Teva Pharmaceutical Industries, the world’s largest manufacturer of generic drugs, would leave the GPhA, saying the lobbying group was no longer capable of reflecting its interests.
“It is with regret that I announce that the board of directors of GPhA has reluctantly accepted the resignation of Kathleen Jaeger as president and CEO of our association,” GPhA chairman and Watson Pharmaceuticals president and CEO Paul Bisaro said. “We are pleased that Ms. Jaeger will remain an adviser to GPhA through the end of 2010 and that she has agreed to work with the association to ensure a smooth transition without interruption in our advocacy activities.”